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Narcotic bowel syndrome (NBS) is 
defined as chronic (more that 3 
months in duration) non-cancer 
abdominal pain, requiring at least 
100 mg of morphine equivalent per 
day in the setting of continued or 
escalating dosages of narcotic pain 
medications with very little or no 
relief in abdominal pain. The 
prevalence of narcotic bowel 
syndrome varies based on the 
population studied and presenting 
symptoms, ranging from 0.19% in 
the general population to 58% in 
patients with chronic non-cancer 
abdominal pain and 9% in patients 
on chronic narcotics with vomiting as 
the major presenting complaint. 
This is a retrospective chart review 
study of health care utilization in 
patients with narcotic bowel syndrome 
in a subspecialty clinic at a tertiary 
care center.  
 
Inclusion criteria were : 
 
1) Adult patients 18 years of age or 
older with chronic non-cancer 
abdominal pain of otherwise 
undetermined etiology  
2) On 100 mg or more of morphine 
equivalent per day  
3) No history of bowel resection or 
Inflammatory Bowel Disease  
4) Non-pregnant 
Medical records of 4723 patients seen in Gastrointestinal Clinic at the University of Kansas Medical Center from 2005 to 2010 were reviewed. Seventy eight patients met inclusion criteria for NBS. Male to female ratio was 1:3 with mean age of 44 years, consuming on average 410 mg of morphine equivalent daily. Duration of abdominal pain ranged from 6 months to 20 years. The disability rate was 74% with hospitalization/ER visit rate of 96% within last year (53% had multiple visits).  The most common accompanying symptoms were nausea and vomiting 80%, constipation 72%, anorexia 68% and abdominal bloating 45%. All aforementioned symptoms were present in 26% of patients with NBS. 96.2% of patients with NBS had at least one abdominal imaging study within the past one year for a total of 544 abdominal imaging studies being done, resulting in average of 7 imaging tests per person.  94.5% of patients had at least one endoscopic evaluation within the past one year: 20.5% had only EGD, 3.9% had only colonoscopy, 57.7% had both and 12.8% had ERCP, upper/lower EUS or both. Health care provider time devoted to these patients during multiple ER/office visits (primary care physicians and gastroenterologists alike) and hospitalizations needs to be taken into consideration as well. Cost analysis can be done in the future to analyze the financial burden. 
The aim of our study was to evaluate 
the healthcare resource utilization in 
patients with narcotic bowel syndrome 
Results 
Medical records of 4723 patients seen in 
the Gastroenterology Clinic at the 
University of Kansas Medical Center 
from 2005 to 2010 were reviewed. 
Seventy-eight patients met inclusion 
criteria for NBS. Male to female ratio 
was 1:3 with mean age of 44 years, 
consuming on average 410 mg of 
morphine equivalent daily.  
Duration of abdomi al pain ranged from 6 months to 20 year . The disability rat  was 74% with hospitalization/ER visit rate of 96% within last year (53% had multiple visits).  The most common acco panying symptoms w re n usea and vomiting 80%, cons ipation 72%, anorexia 68% and abdominal bloating 45%. All aforemention d sympto s were present in 26% of patients with NBS. 96.2% of patients with NBS had at least ne bdominal imaging study within the past one year f r a total of 544 abdominal imaging studies being done, resulting in v rage of 7 imaging tests per p rson.  94.5% of patients had at least one endoscopic ev luation within the past one year: 20.5% had only EGD, 3.9% had only colonoscopy, 57.7% had both a d 12.8  had ERCP, upper/lower EUS or both. Health care provider time devoted to these patients during multiple ER/ ffice visits (primary care physicians and gastroenterologists alike) and hospitalizations needs to be taken into consideration as well. Cost a alysis can be done in the future to analyze the fi ancial burden. 
Duration of abdominal pain ranged from 
6 months to 20 years. The disability rate 
was 74% with hospitalization/emergency 
room  visit rate of 96% within last year 
(53% had multiple visits).   
The most common accompanying 
symptoms were nausea and vomiting 
80%, constipation 72%, anorexia 68% 
and abdominal bloating 45%. All 
aforementioned symptoms were present 
in 26% of patients with NBS.  
96.2% of patients with NBS had at least 
one abdominal imaging study within the 
past one year for a total of 544 
abdominal imaging studies being done, 
resulting in an average of 7 imaging 
tests per person.  94.5% of patients had 
at least one endoscopic evaluation 
within the past one year, out of which 
20.5% had only EGD, 3.9% had only 
colonoscopy, 57.7% had both and 
12.8% had ERCP, upper/lower EUS or 
both.  
Health care provider time devoted to 
these patients during multiple 
emergency room/office visits (primary 
care physicians and gastroenterologists 
alike) and hospitalizations needs to be 
taken into consideration as well.  
Cost analysis can be done in the future 
to analyze the financial burden. 
NBS is comm n in patients taking opiates for ch onic non-cancer pai  and is ssociat d with a larg  burd n on health c re utiliz tion. Better physician education directed at recogniti n of NBS as an etiol gy of abdominal pai  and judicious use of opiates e r quired t  m nimize exhaustive, repe itive ev luations.  
Narcotic Bowel Syndrome is 
common in patients taking opiates  
for chronic non-cancer pain and is 
associated  with  a large burden 
on health care utilization.  Better 
physician education directed at 
recognition of narcotic bowel  
syndrome as an etiology of 
abdominal pain   and judicious 
use of opiates are required  in 
order to minimize exhaustive, 
repetitive, costly evaluations.  
is common in patients taking opiates for chronic non-cancer pain and is associated with a large burden on health care utilization. Better physician education directed at recognition of NBS as an etiology of abdominal pain and judicious use of opiates are required to minimize exhaustive, repetitive evaluations.  
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